Ceramides as biomarkers for heart attack and diabetes?

Link to obesity and diabetes

It has already been shown in rodents that ceramides are involved in the regulation of inflammation, insulin resistance and stress: increasing the expression of the ceramide synthesis enzyme (CerS-6) and increasing Cer-16 made the animals particularly susceptible to insulin resistance, In contrast, mice without CerS-6 were protected against obesity and glucose intolerance, scientists found in a study published in Cell in 2014 (“Obesity-Induced CerS6-Dependent C16:0 Ceramide Production Promotes Weight Gain and Glucose Intolerance”) . “These experiments show that inhibition of CerS6 is a specific approach for the treatment of obesity and type 2 diabetes mellitus,” the researchers explained at the time. Now, mice are not humans, but there are already data from epidemiological studies for humans that link ceramides, dihydroceramides and cardiovascular diseases (“European Heart Journal”: “Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients”) and for the specific ceramides Cer-18, Cer-20 and Cer-22 to type 2 diabetes mellitus (“The Journal of Nutrition”: “Plasma Ceramide Species Are Associated with Diabetes Risk in Participants of the Strong Heart Study”).

See also  The wind is blowing ? Wear the mask against Covid-19!

Share:

Facebook
Twitter
LinkedIn

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

On Key

Related Posts